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Abstract
Maternal-fetal cellular trafficking is the bidirectional passage of cells between the fetus and mother during pregnancy. The 
presence of fetal cells in maternal circulation, brain, and muscles is known as fetal microchimerism . During pregnancy, fetal 
cells can be obtained from the mother’s blood for prenatal diagnosis of the fetus. Furthermore, it has been confirmed that fetal 
microchimerism persists decades later in women who have been pregnant . Investigation of the long-term consequences of fetal 
microchimerism is a frontier of active study, with preliminary results pointing to both beneficial and adverse effects. This review 
will examine the relevant literary information on fetal microchimerism during pregnancy and provide current knowledge regarding 
the long-term effects of naturally acquired fetal microchimerism .
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Introduction
Microchimerism is the presence of two genetically dis-
tinct cell populations in the same individual. Foreign 
cells and DNA are found in an individual’s plasma or 
tissues that originated from a genetically different indi-
vidual. Naturally acquired microchimerism is commonly 
observed and results from the maternal-fetal exchange 
of cells and DNA during pregnancy. (Gammill & Nelson 
2010) In pregnancy, there is transplacental two-way 
trafficking of living fetal cells from the fetus into the 
maternal circulation, and cells from maternal circulation 
impart in the fetus. (Naik, Shrivastava, Suryawanshi, & 
Gupta 2019) This paper provides an overview of the 
role of fetal cell microchimerism in autoimmune and 
cancerous diseases. The mechanisms by which fetal mi-
crochimerism is believed to modulate the protection 
against cancer or tumor progression will be discussed, 
along with future research directions. 
Methods
This document was written by researching peer-reviewed 
scholarly articles and medical journals to assess the 
newest research and methods in fetal microchimerism. 
The information and data were gathered from numer-
ous sources, including databases such as Google Scholar, 
Touro Library, The National Center for Biotechnology 
Information, and The National Institute of Health. Key-
phrases searched included, “fetal microchimerism,” “the 
effects of fetal microchimerism,” and “fetal microchi-
merism in autoimmune disorders.” All the content was 
carefully selected, compared, and analyzed to assure its 
validity and determine the articles’ standpoint.
Fetal Microchimerism
Microchimerism is the fetus’s cell legacy after pregnancy. 
Fetal stem cells can leave the fetus and migrate across 
the placenta to engraft in the maternal bone marrow and 
other tissues. The transfer of fetal progenitor stem cells 
begins four or five weeks after fertilization and continues 
throughout the pregnancy. This form of microchimerism 
occurs in both male and female embryos, but the detec-
tion of male microchimerism in maternal tissue is easier 
to detect due to the unique presence of Y-chromosome 
in the women. (Miech, 2010)   
Fetal microchimerism has been reported in the periph-
eral blood of women in cellular subsets, including lym-
phoid-lineage and myeloid-lineage cells. An experiment was 
done to evaluate microchimerism in CD66b sorted gran-
ulocytes. Granulocytes were isolated from the peripheral 
blood of healthy women. CD66b+ cells were then isolated 
by fluorescence-activated cell sorting, and a panel of poly-
morphism-specific quantitative assays was employed to 
investigate the presence of fetal and maternal microchime-
rism. One-third of the women tested positive for at least 
one form of microchimerism. 40% had maternal microchi-
merism compared to 15% who had fetal microchimerism. 
The maternal and fetal origin CD66b+ cells are strong evi-
dence for an active microchimeric hematopoietic stem and 
progenitor cell niche. Higher proportions of women might 
test positive for even larger quantities of microchimerism if 
more sensitive assays were available.  (Sunku, Gadi, Lacoste, 
Guthrie, & Nelson, 2010)
Fetal DNA in Maternal Plasma During Pregnancy 
Another study was undertaken to evaluate fetal DNA 
in maternal plasma and urine. DNA was isolated from 
plasma and urine samples of 80 pregnant women, ranging 
from 7 to 40 weeks of gestation. Their DNA underwent 
amplification for Y specific chromosome DNA via a nest-
ed polymerase chain reaction. The postpartum analysis of 
fetal gender showed that 25 women carried female fe-
tuses and 55 male fetuses. Among the 55 women bearing 
male fetuses, Y chromosome‐specific signals were detect-
ed in 96% of their plasma and 38% of their urine samples. 
(Al-Yatama et al., 2001) The detection of fetal sex chro-
mosomes with Y-chromosome-PCR has a specificity of 
100% and a sensitivity of 96%, which increases along with 
gestational age. This minor lack of sensitivity explains why 
Y-chromosome signals were only located in 96% of the 
plasma of pregnant women. (Rijnders et al.) The analysis 
of their results with respect to gestational age showed no 
significant difference in the Y chromosome‐specific DNA 
detection. These results showed that fetus‐specific DNA 
was detected in the maternal plasma by nested PCR. (Al-
Yatama et al., 2001) 
Fetal DNA is present in low concentration in maternal 
plasma increasing throughout pregnancy with a 0.1% in-
crease each week from 10 to 20 weeks’ gestation, followed 
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by a 1% increase each week from the 21st week until term. 
(Taglauer et al.) Clinical tests have tried to capitalize on 
this DNA to identify the baby’s sex, determine whether 
the child and mother have Rh incompatibility, and identify 
chromosomal disorders. (LeslieDec, et al. 2017) 
Many early investigations of fetomaternal cell traffick-
ing sought to develop methods whereby noninvasive 
prenatal diagnosis of genetic disorders could be achieved. 
(Gammill & Nelson 2010) Noninvasive testing would 
ameliorate the risk of fetal miscarriage associated with 
current invasive procedures such as amniocentesis. This 
non-invasive prenatal test is a blood test, and between 
25 and 42.5 milliliters are collected.  (Bianchi, Williams, 
Pelletier, Klinger, & Shuber 1996) The main conditions for 
which prenatal diagnosis is considered are monogenic dis-
eases, when the causation of the disease results from one 
gene, and therefore, is easier to detect and obtains con-
clusive results. Fetal DNA circulates in a high background 
of maternal DNA and is isolated and amplified using poly-
merase chain reaction technology. However, even after 
that, maternally inherited fetal alleles are very difficult to 
identify from maternal plasma, therefore, scientists have 
focused on the detection of paternally inherited fetal al-
leles that are not present in the maternal genome. The 
diagnosis of autosomal dominant diseases transmitted by 
the father could be made noninvasively. Also, by detecting 
the paternally inherited fetal alleles, one can exclude the 
fetal inheritance of autosomal recessive diseases. The dis-
covery of free cellular fetal DNA in maternal plasma has 
offered new approaches for noninvasive diagnosis, and 
fetal isolation analysis is now possible. (Lun et al., 2008)  
Fetal DNA in Maternal Plasma After Pregnancy
Microchimerism occurs as a result of the fetomaternal 
transfusion of blood cells across the placenta during preg-
nancy. After delivery, once the placenta has been expelled, 
fetal-origin cells should hypothetically depart from the 
maternal circulation. Nevertheless, studies of women who 
had given birth to a male child showed a high incidence 
of male cells in their blood after delivery. Additionally, 
some women have displayed male cells in their tissues 
up to 27 years postpartum after having birthed a male 
child. This event can be interpreted to mean that fetal 
cells transferred from the fetus to the mother during 
pregnancy established permanent microchimerism in the 
maternal body. This permanency was reported in 30–50% 
of women who gave birth to a male child. (Sato, Fujimori, 
Sato, & Ohto, 2008)   
There is an increased fetal-to-maternal transfer of pro-
genitor cells during an abortion procedure as the pla-
centa is being destroyed. Maximized fetal cell trafficking 
following a medical abortion was confirmed in an in vivo 
model. Since the embryonic circulatory system is estab-
lished in the first trimester of pregnancy, there is a greater 
chance for the transfer of a larger number of progenitor 
T cells during the first-trimester termination of pregnan-
cy. Therefore, women who had an elective abortion in 
their first or second trimester have a greater tendency 
towards fetal microchimerism. (Miech, 2010)   
Male microchimerism in women without sons and the 
correlation of microchimerism to prior pregnancy history 
was researched. Y-chromosome-specific quantitative PCR 
was used to test peripheral blood mononuclear cells of 
120 women. Women were categorized into four groups 
based on their pregnancy histories. Group A was nulli-
gravid and displayed 10% male microchimerism, Group B 
had induced abortions and displayed 57%, Group C had 
spontaneous abortions and displayed 22%, and Group 
D had only daughters and displayed 8%. Male micro-
chimerism prevalence was the greatest by a significant 
amount in those with induced abortions. Other possible 
sources of male microchimerism, such as those obtained 
in Groups A and D, include unrecognized spontaneous 
abortion or a vanished male twin. (Yan et al., 2005) 
Autoimmune Effects on The Mother
It has been theorized that the persistence and abundance 
of fetal microchimerism are dependent on numerous fac-
tors, including the immunogenetic relationships between 
mother and fetus, and perhaps between and preexisting 
inhabitants of the maternal system, from her mother or 
previous children. (Gammill & Nelson 2010) 
Fetal microchimerism, a form of trans-placental stem 
cell transplant, helps to explain the etiology, diversity of 
tissue pathology, predilection for females, and increase in 
the annual incidence of autoimmune diseases in women. 
(Miech, 2010) Fetal stem cells can differentiate into 
mature and competent cells, such as lymphocytes and 
monocytes. Fetal cells in maternal circulation or tissues 
may mediate a graft vs. host disease, which can lead to the 
development of autoimmune diseases. Women comprise 
80% of people with autoimmune diseases. Researchers 
have begun investigating the association of micro-chime-
rism with autoimmune diseases that predominately affect 
women. (Naik, Shrivastava, Suryawanshi, & Gupta 2019)   
Fetal microchimeric cells in maternal tissues led to the 
discovery of a positive correlation between fetal microchi-
merism and autoimmune diseases in women. Progenitor 
cells in the fetal immune system, such as T cells, mono-
cytes, macrophages, lymphocytes, and NK cells, are among 
the many fetal cell types that can be transferred to ma-
ternal tissues. In maternal tissues, the fetal microchimeric 
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progenitor immature T cells are capable of self-renewal, 
proliferation, and differentiation. Progenitor cell activation 
can result in the production of autocrine and paracrine in-
flammatory responses in autoimmune diseases. Triggering 
agents that activate these fetal microchimeric immune cells 
to attack the maternal host cells resulting in autoimmune 
disease have not yet been identified. Suspected triggers 
include viral or bacterial agents, abnormal localized tissue 
protein, and drugs. Microchimerism in affected tissues is 
more likely to be abundant in women with autoimmune 
diseases than in women with non-autoimmune diseases. 
(Miech, 2010)  
Pregnancy alters symptoms of autoimmune diseases. 
The maternal immune system develops a tolerance to 
the fetus, and the suppression of the maternal response is 
lifted postpartum. Fetal tolerance may explain why some 
autoimmune disease symptoms decrease during pregnan-
cy in some women. (Boddy, Fortunato, Sayres, & Aktipis, 
2015) Autoimmune diseases are often repressed during 
pregnancy and exasperate postpartum. It was then hy-
pothesized that fetal cells in maternal circulation might be 
important in influencing autoimmune disease in pregnancy 
and postpartum. (Ando, Imaizumi, Graves, Unger, & Davies, 
2002) Systemic sclerosis provided the first evidence for 
the involvement of fetal microchimerism with autoim-
mune diseases. Patients frequently had fetal cells not only 
in peripheral blood, but also in skin lesions. The hyperthy-
roidism of Graves’ disease frequently abates during preg-
nancy and exacerbates after childbearing. (Ando, Imaizumi, 
Graves, Unger, & Davies, 2002) Between 43 and 75% of 
patients with rheumatoid arthritis exhibit amelioration of 
some or all their rheumatoid arthritis symptoms during 
pregnancy. Additionally, in rheumatoid arthritis patients, 
symptoms tend not only to show improvement during 
pregnancy, but an exacerbation of symptoms postpartum. 
Correspondingly, the rate of relapse declines with pregnan-
cy in women diagnosed with multiple sclerosis, with the 
lowest rate in the third trimester. Relapse rates return to 
pre-pregnancy levels postpartum. This framework suggests 
that a contributor to autoimmune disease development 
may be the maternal immune response to the presence of 
fetal cells that invade maternal tissues. (Boddy, Fortunato, 
Sayres, & Aktipis, 2015)  
The risk of developing an autoimmune disease in parous 
women is higher after the first year postpartum. Fetal cells 
in the thyroid may contribute to thyroid cancer risk or 
susceptibility to other thyroid diseases. Current research 
suggests an association with postpartum thyroid tissue 
and thyroid diseases. Fetal cells are more abundant in the 
thyroid tissue and blood of women with Graves’ disease 
and Hashimoto’s thyroiditis, compared to healthy controls. 
Also, the risk of autoimmune disease in parous women 
is significantly higher after the first year postpartum. This 
knowledge suggests that the presence of fetal cells in the 
thyroid is associated with a maternal disease rather than 
health. (Boddy, Fortunato, Sayres, & Aktipis, 2015) 
Autoimmune thyroid disease affects reproductive-aged 
women. It commonly initiates or exacerbates postpartum, 
and so the involvement of fetal microchimerism was sus-
pected. Autoimmune thyroid disease does have e a profound 
relationship with pregnancy. Autoimmune thyroid disease in-
volves autoimmune antigens, such as the TSHR, Tg, and TPO. 
Placental immune suppression during pregnancy lessens the 
activity of autoimmune thyroid disease, as seen in the re-
mission of Graves’ disease. However, exacerbation of preex-
isting autoimmune thyroid diseases or initiation of autoim-
mune thyroid disease is also common postpartum. Increased 
titers of thyroid autoantibodies have been observed in the 
postpartum. Graves’ disease has also been shown to be 
most markedly suppressed by pregnancy itself, but; however, 
up to 60% of Graves’ disease patients of childbearing age 
have been reported to develop this disease within one year 
of delivery. (Ando & Davies, 2003) 
Cancerous Effects on the Mother
During pregnancy, fetal cells enter the maternal body, 
cross the placenta, and are found frequently in the ma-
ternal lung. It was generally accepted that the fetal cells 
in the lung were passing through the mother’s pulmonary 
circulation; however, the presence of fetal cells in the lung 
shows an association with cancer. A study reported high-
er levels of male DNA and significantly more fetal cells in 
the lung and thymus tissue in the diseased lung compared 
to healthy bone marrow from the same person. (Boddy, 
Fortunato, Sayres, & Aktipis, 2015) Fetal cells have also 
been detected as clusters in lung tumors in women de-
cades after pregnancy. Their tumor frequency was higher 
in lung tumors than in the healthy surrounding lung tissue. 
The fetal cells may be recruited from the bone marrow 
to the tumor sites where they assumed their role in 
immunosurveillance and tissue repair. (Naik, Shrivastava, 
Suryawanshi, & Gupta 2019) 
Fetal cells are frequently found in normal breast tissue 
postpartum women. The research presents a complicated 
picture of fetal cell’s role in breast cancer. Fetal cells are 
found less the tissue and blood of women with breast 
cancer compared to healthy controls. (Boddy, Fortunato, 
Sayres, & Aktipis, 2015) It was reasoned that naturally 
acquired allogeneic immune cells in the form of fetal mi-
crochimerism might correlate with protection from the 
development of breast cancer. Fetal microchimerism was 
found in higher quantities in healthy women compared 
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to breast cancer patients, 43% to 14%, respectfully. This 
shows a correlation between the role of fetal allogeneic 
cells as malignant cell immune surveillance and protection 
from breast cancer. (Gadi & Nelson, 2007)  
Reduced risk of breast cancer is recognized among 
parous compared to nulliparous women. Eighty-two 
women were tested for male DNA in peripheral blood, 
presumed from a prior pregnancy with a male fetus. Forty-
seven of the subjects were healthy, and 35 had breast can-
cer. The levels of male DNA were determined by real-time 
PCR for a Y chromosome-specific gene in DNA extracted 
from peripheral blood mononuclear cells. Fetal microchi-
merism was found in 43% of healthy women and 14% in 
women with breast cancer. These findings suggest that allo-
geneic fetal microchimerism may contribute to a reduction 
in the risk of breast cancer. (Gadi & Nelson, 2007) 
Through the evolutionary history of fetal microchime-
rism in the maternal body, it is possible that it now has 
a role in normal breast tissue physiology. The maternal 
mammary gland hosts stem cells that contribute to the 
development of normal breast tissue and can be trans-
ferred to the neonate during lactation. Mouse fibroblast 
fetal cells have been shown to differentiate into mammary 
epithelioid cells when exposed to lactation hormones in 
vitro, and a functional mammary gland has been generated 
from a single stem cell in a pregnancy mouse model. This 
suggests that fetal progenitor cells play a role in breast 
morphology and maternal milk supply. (Boddy, Fortunato, 
Sayres, & Aktipis, 2015)  
Pregnancy at older ages has been linked to risk for 
ovarian cancer. Given the data that microchimeric cells in 
parous women decline overtime after pregnancy, and that 
ovarian cancer develops most commonly in postmeno-
pausal women, fetal microchimerism may play a protec-
tive role in ovarian cancer as well. (Naik, Shrivastava, 
Suryawanshi, & Gupta 2019)
Neurological Effects on the Mother 
It was unknown whether fetal cells, which are capable of 
crossing the placental barrier to enter maternal blood, 
could also cross the blood-brain barrier and enter the 
maternal brain. To determine if fetal cells could enter the 
maternal brain during pregnancy, female wild‐type mice 
were crossed with green mice. Their offspring ubiquitous-
ly expressing the enhanced green fluorescent protein. 
Green mouse fetal cells were found in the maternal brain, 
and quantitative real‐time PCR of genomic DNA for the 
enhanced green fluorescent protein gene showed that 
more fetal cells were present in the maternal brain for 
weeks postpartum than on the day of birth. After an exci-
totoxic lesion to the brain, more fetal cells were detected 
in the injured region. For weeks postpartum, enhanced 
green fluorescent protein‐positive green mouse fetal 
cells in the maternal brain were found to adopt locations, 
morphologies, and expression of immunohistochemical 
markers indicative of astrocytes, neurons, oligodendro-
cyte, and macrophage-like cell types. The expression of 
morphological and histochemical characteristics of these 
cells was confirmed on the identification of fetal cells in 
the maternal brain by Y chromosome fluorescence hy-
bridization. The characterization of these cells that allow 
them to cross both the placental and blood-brain barri-
ers and to target the injured brain may improve selection 
procedures for isolation of stem or progenitor cells for 
brain repair by infusions. (Tan et al., 2005) 
Several studies have found male DNA in human and ma-
ternal mouse brains, but the function of these cells is not 
entirely known. One study found that fetal cell DNA in nu-
merous regions of the maternal brain, even decades after 
the woman had birthed a son, suggesting that fetal micro-
chimerism in the human maternal brain may be long-lasting. 
(Boddy, Fortunato, Sayres, & Aktipis, 2015) A team led by 
autoimmunity researcher, J. Lee Nelson sought to discover 
how leftover fetal cells affect the brain. They took samples 
from autopsied brains of 59 women. Male DNA evidence 
was found in the brains of 63% of the participants. The male 
DNA was scattered across several brain regions. Studies 
have hypothesized that the risk of Alzheimer’s disease in-
creases with an increasing number of pregnancies, so the 
team also examined the brains for signs of the disease. Of 
the 59 women, 33 had Alzheimer’s disease. Compared to 
healthy controls, fetal cells were found to be less common 
in the brains of women who had Alzheimer’s disease. That 
correlation suggests that the presence of fetal cells in the 
maternal brains helps protect women against Alzheimer’s 
disease. (PhillipsSep, et al. 2017)  
Conclusion
The placenta is unique because it allows for intimate con-
tact between maternal and fetal cells at the maternal-fe-
tal interface throughout pregnancy. (Than et al.) During 
pregnancy, the semi-allogeneic fetus is protected from 
rejection by the maternal immune system. (Trowsdale and 
Betz) It was hypothesized that the semi allogeneic fetus 
could survive due to the regulation of the immunologic 
interactions between mother and fetus. Such regulation 
can be caused by functional suppression of the maternal 
immune response or a lack of fetal antigen expression. 
(Morelli et al.)   
In the human placenta, fetal trophoblast cells do not 
express MHC HLA-A and B molecules, which are re-
sponsible for allograft rejection in humans. (Chen et al.) 
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Mixed hematopoietic chimerism, the state in which bone 
marrow hematopoietic stem cells from two genetically 
different animals coexist, remains the most robust tool 
for tolerance induction. Unfortunately, bone marrow 
or hematopoietic stem cell transplantation for patients 
awaiting solid organ transplantation remains at high-
risk, due to the dangers of graft-versus-host disease. 
(Zavazava) Human embryonic stem cells express low 
levels of (MHC)-I antigens and lack expression of MHC-II 
antigens. These stem cells must engraft in the transplant 
recipient, inducing tolerance to foreign cells, and reducing 
the immune targeting of the transplant. Upon injection 
into immunocompetent mice, human embryonic stem 
cells are unable to produce an immune response. Human 
embryonic stem cells may provide a potential tool for the 
induction of immunotolerance. Further studies in human 
embryonic stem cells immunobiology are warranted and 
may reveal unique mechanisms that account for the im-
munological properties of human embryonic stem cells. 
(Menendez et al.) 
Fetal cells and DNA go beyond the womb and into 
maternal blood and tissues during pregnancy and can last 
long after birth.  In some instances, fetal microchimerism 
contributes to perturbations in maternal immunity that 
may contribute to autoimmune diseases. In other cases, 
these interactions seem to benefit long-term maternal 
health by allowing fetal microchimerism cells to act as 
allogeneic surveyors in her system. Fetal microchime-
rism has potential implications for the understanding of 
women’s health and disease pathology postpartum. The 
pregnant mother mshould never be viewed as merely an 
incubator. Rather, microchimerism expands the biological 
bonds that are established between the pregnant mother 
and her fetus. 
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